Immunovant
IMVT
186 hedge funds and large institutions have $1.53B invested in Immunovant in 2025 Q3 according to their latest regulatory filings, with 35 funds opening new positions, 65 increasing their positions, 50 reducing their positions, and 16 closing their positions.
119% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 16
50% more funds holding in top 10
Funds holding in top 10: 4 → 6 (+2)
30% more repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 50
11% more funds holding
Funds holding: 168 → 186 (+18)
0% less capital invested
Capital invested by funds: $1.54B → $1.53B (-$5.54M)
1.7% less ownership
Funds ownership: 56.3% → 54.6% (-1.7%)
41% less call options, than puts
Call options by funds: $7.15M | Put options by funds: $12.1M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$27.6M |
| 2 |
AC
Armistice Capital
New York
|
+$10.3M |
| 3 |
TSC
Two Seas Capital
Rye,
New York
|
+$8.24M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$6.79M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$6.41M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$62.6M |
| 2 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$27.8M |
| 3 |
PA
Perceptive Advisors
New York
|
-$8.9M |
| 4 |
Pictet Asset Management
Carouge,
Switzerland
|
-$8.29M |
| 5 |
JP Morgan Chase
New York
|
-$6.52M |
IMVT Hedge Fund Activity: Q3 2025 in Review
186 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Immunovant (IMVT) for Q3 2025, worth a combined $1.53B — down 0.36% from $1.54B a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new IMVT positions and 16 closed out — a net gain of 19 holders — while 65 added to existing stakes and 50 trimmed.
The largest buyer was ADAR1 Capital Management, adding an estimated $27.6M. The largest seller was Fidelity Investments, cutting an estimated $62.6M.
- 186 institutional investors held Immunovant (IMVT) as of Q3 2025, up from 168 in Q2 2025.
- Funds reported $1.53B of Immunovant stock for Q3 2025, down 0.36% quarter-over-quarter.
- 35 funds opened new Immunovant positions in Q3 2025 and 16 closed out, a net change of +19 holders.
- The largest Immunovant buyer in Q3 2025 was ADAR1 Capital Management, an estimated $27.6M added.
- The largest Immunovant seller in Q3 2025 was Fidelity Investments, an estimated $62.6M sold.
Based on aggregated 13F filings for Q3 2025.